Nothing Special   »   [go: up one dir, main page]

UA114792C2 - Glucagpn/glp-1 receptor co-agonists - Google Patents

Glucagpn/glp-1 receptor co-agonists

Info

Publication number
UA114792C2
UA114792C2 UAA201400131A UAA201400131A UA114792C2 UA 114792 C2 UA114792 C2 UA 114792C2 UA A201400131 A UAA201400131 A UA A201400131A UA A201400131 A UAA201400131 A UA A201400131A UA 114792 C2 UA114792 C2 UA 114792C2
Authority
UA
Ukraine
Prior art keywords
glp
receptor
glucagpn
agonists
peptide
Prior art date
Application number
UAA201400131A
Other languages
Ukrainian (uk)
Inventor
Річард Д. Дімарчі
Девід Л. Смайлі
Original Assignee
Індіана Юніверсіті Рісьорч Енд Текнолоджі Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Індіана Юніверсіті Рісьорч Енд Текнолоджі Корпорейшн filed Critical Індіана Юніверсіті Рісьорч Енд Текнолоджі Корпорейшн
Priority claimed from PCT/US2012/042084 external-priority patent/WO2012177443A2/en
Publication of UA114792C2 publication Critical patent/UA114792C2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Винахід належить до пептиду або його фармацевтично прийнятної солі, які демонструють підвищену активність на GLP-1-рецепторі, порівняно з нативним глюкагоном, фармацевтичної композиції, що містить вказаний пептид або його фармацевтично прийнятну сіль, способу лікування та їх застосування.The invention relates to a peptide or its pharmaceutically acceptable salts, which exhibit increased activity on the GLP-1 receptor, in comparison with the native glucagon, of a pharmaceutical composition containing said peptide or its pharmaceutically acceptable salt, method of treatment and use thereof.

UAA201400131A 2011-06-22 2012-06-12 Glucagpn/glp-1 receptor co-agonists UA114792C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161500027P 2011-06-22 2011-06-22
PCT/US2012/042084 WO2012177443A2 (en) 2011-06-22 2012-06-12 Glucagon/glp-1 receptor co-agonists

Publications (1)

Publication Number Publication Date
UA114792C2 true UA114792C2 (en) 2017-08-10

Family

ID=59521684

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201400131A UA114792C2 (en) 2011-06-22 2012-06-12 Glucagpn/glp-1 receptor co-agonists

Country Status (1)

Country Link
UA (1) UA114792C2 (en)

Similar Documents

Publication Publication Date Title
CY1124135T1 (en) DOSAGE FORMS FOR THE TREATMENT OF ROMRE'S DISEASE
UA114710C2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
CL2014003421A1 (en) Glucagon analogs exhibiting agonist activity at the glusose-dependent insulinotropic peptide receptor (gip): pharmaceutical composition; and method to reduce weight gain or induce weight loss, particularly for the treatment of obesity.
MX2013015168A (en) Glucagon/glp-1 receptor co-agonists.
MX2013015176A (en) Glucagon/glp-1 receptor co-agonists.
CL2013002053A1 (en) Heterocyclic derivative compounds, glucagon receptor antagonists; pharmaceutical composition that includes it and its use in the treatment of diabetes and metabolic diseases. pct
UA117103C2 (en) Glucagon analogues
CL2013003454A1 (en) Pharmaceutical composition for preventing or treating diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate.
MX2016006053A (en) Selective pyy compounds and uses thereof.
NZ612297A (en) Glucagon analogs exhibiting gip receptor activity
CL2014001994A1 (en) Synthetic apeline mimetic polypeptide for treatment and heart failure; pharmaceutical composition comprising said polypeptide.
EA201370178A1 (en) STABLE COMPOSITIONS FOR PARENTERAL INJECTION OF PEPTIDE MEDICINES
MX2020010693A (en) Use of long-acting glp-1 peptides.
CY1119798T1 (en) FORM IV IV Hydrochloride Ibabradine
CL2014001437A1 (en) Compounds derived from aryl dihydropyridinone and piperidinone as inhibitors of monoacrylic glycerol acyltransferase (mgat2); pharmaceutical composition and combination; and use in the treatment and prevention of diabetes, hyperglycemia, retinopathy, metabolic syndrome, among other diseases.
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
CY1117603T1 (en) LIXISENATIDE AS AN ADDITION TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
EA201600442A1 (en) SOFT PHARMACEUTICAL COMPOSITION ON WATER BASIS CONTAINING TAPENTADOL
CL2014001861A1 (en) Compounds derived from benzyl sulfonamide, mogat-2 inhibitors; crystalline compound; pharmaceutical composition; and its use in the treatment of hypertriglyceridemia.
CR20170314A (en) FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP
EA201491258A1 (en) Self-flashing catheters
CL2014001705A1 (en) Compounds derived from aza adamantane, 11beta-hsd-1 inhibitors; pharmaceutical composition; method for prevention or treatment; and use to prevent or treat metabolic syndrome, type 2 diabetes as a result of obesity, insulin resistance, dyslipidemia, neuropathy, ischemia and infarction, among other diseases.
MX2016007682A (en) Pharmaceutical composition comprising amorphous ivabradine.
EA201490041A1 (en) PLASTER CONTAINING DICLOFENAC AND THYOKOLCHICOSID